![logo](/logos/NEXI.webp)
NexImmune, Inc.
NASDAQ:NEXI
0.34 (USD) • At close September 5, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | NexImmune, Inc. |
Symbool | NEXI |
Munteenheid | USD |
Prijs | 0.371 |
Beurswaarde | 711,281 |
Dividendpercentage | 0% |
52-weken bereik | 0.34 - 28.695 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Ms. Kristi Jones R.Ph. |
Website | https://www.neximmune.com |
An error occurred while fetching data.
Over NexImmune, Inc.
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy,
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)